TCD601 for Kidney Transplant Tolerance
(PERSPECTIVE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing TCD601 to help new kidney transplant patients from living donors accept their new organ without immune system rejection.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the study team for guidance.
Is TCD601 (Siplizumab) safe for human use?
How is the drug TCD601 different from other treatments for kidney transplant tolerance?
TCD601, also known as siplizumab, is unique because it is a humanized monoclonal antibody that targets CD2, a molecule on immune cells, to help prevent kidney transplant rejection. This mechanism is different from other treatments that often target different immune pathways or use a combination of therapies.13467
What data supports the effectiveness of the drug TCD601 for kidney transplant tolerance?
The research on siplizumab, a component of TCD601, shows it has potential in preventing kidney transplant rejection by targeting specific immune cells. Additionally, similar treatments like Lulizumab have shown success in prolonging kidney graft survival in animal studies, suggesting that TCD601 might also help in improving transplant outcomes.13789
Who Is on the Research Team?
Tracy Killingsworth
Principal Investigator
Nefro Avillion
Are You a Good Fit for This Trial?
This trial is for adults aged 18 to 60 who are receiving their first or second kidney transplant from a living donor who's at least half-matched genetically and has the same blood type. Participants must understand the study and agree to its terms. Pregnant women, those able to have children, or individuals with a history of cancer cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Conditioning and Treatment
Participants receive TCD601 with non-myeloablative conditioning and standard of care immunosuppression
Follow-up
Participants are monitored for safety, tolerability, and activity of the treatment regimen
What Are the Treatments Tested in This Trial?
Interventions
- TCD601
Find a Clinic Near You
Who Is Running the Clinical Trial?
ITB-Med LLC
Lead Sponsor